• Proprietary machine-learning reconstruction algorithm trained on 15 years of breast CT data positions IzoView to redefine global imaging standards
• Self-supervised approach works on X-ray data before reconstruction, avoiding the delays that cripple competing AI methods
• Trade secret protection and modality-specific training create durable competitive moats in a crowded, commoditized AI field

The medical imaging industry stands at a pivotal juncture. Artificial intelligence promises to revolutionize diagnostics, yet most AI applications in CT imaging remain stuck in theory rather than practice. Conventional AI denoising tools either demand prohibitive computing power, compromise diagnostic clarity, or require impractical training datasets that increase patient exposure. The gap between AI’s promise and clinical reality has created a rare opportunity for innovators who can bridge it.

At the heart of sustainable differentiation lies data and intellectual property. As general-purpose AI models become commoditized, long-term advantage comes from domain-specific training, proprietary datasets, and protected algorithms designed for real-world clinical workflows. This is where Izotropic (CSE: IZO) (OTCQB: IZOZF) is carving out a moat with its IzoView Breast CT system.

In partnership with Johns Hopkins University School of Medicine, Izotropic has developed a proprietary machine-learning reconstruction algorithm for its IzoView Breast CT Imaging System. The technology addresses the long-standing trade-off between image quality and radiation dose.

Lower doses protect patients but produce noisy, grainy images that limit diagnostic confidence. Traditional fixes fall short: Model-Based Iterative Reconstruction (“MBIR”) requires minutes per image, untenable when breast CT generates up to 500 images per scan, while Deep Machine Learning Reconstruction (“DMLR”) needs paired high/low-dose scans, increasing radiation exposure and confusing algorithms with correlated noise.

Workflow-Compatible Approach

IzoView’s algorithm flips the script. Instead of cleaning images after reconstruction, it works directly on raw X-ray detector data before reconstruction begins. This shift enables superior denoising without altering natural breast tissue texture.

The self-supervised method eliminates the bottlenecks of MBIR and the unsafe training demands of DMLR. For the first time, clinicians can get optimized images at lower doses without sacrificing workflow efficiency, an innovation with immediate clinical relevance.

By solving the practical barriers that have kept AI out of breast CT, Izotropic positions IzoView to set new global standards for image quality, patient safety, and regulatory benchmarks in breast imaging.

The algorithm’s real edge lies in its foundation: 15 years of breast CT–specific imaging data. This dataset is deep, highly specialized, and nearly impossible for competitors to replicate without similar decades-long investment and clinical collaboration.

Breast CT is a technically unique modality, distinct from general CT. Models trained on generic datasets consistently fail in this domain. Izotropic’s accumulated data not only gives it a defensible lead but also creates a flywheel effect: better algorithms generate better data, which in turn improves algorithms, widening the moat year after year.

Protected by Trade Secrets, Not Patents

Izotropic has opted for trade secret protection rather than patents, keeping the algorithm’s architecture and training methods undisclosed indefinitely. This strategy avoids the disclosure requirements of patents while making reverse engineering exceedingly difficult.

Combined with the proprietary dataset, trade secret protection creates a multi-layered defense. At a time when large language models and generalized AI systems risk commoditization, modality-specific, data-rich, and legally shielded solutions like IzoView’s represent the true scarce assets in healthcare AI.

Positioned for AI-Driven Healthcare Evolution

The integration of IzoView’s algorithm aligns with two unstoppable healthcare trends: AI adoption and precision diagnostics. Radiologists increasingly rely on computer-aided tools, but these tools are only as good as the data they process. By delivering high-quality, low-dose images, IzoView creates the optimal input for next-generation AI diagnostic platforms.

The approach also strengthens regulatory positioning, since low radiation exposure and high diagnostic accuracy are both critical review criteria. Clinically, it delivers measurable value: improved diagnostic confidence, safer protocols, and no disruption to screening workflows.

Market Implications

IzoView’s AI-enhanced platform differentiates it from legacy CT systems and new AI entrants alike. Instead of theoretical performance gains that falter in real-world settings, Izotropic has focused on practical, deployable solutions. That focus translates into value propositions across the clinical, operational, and economic spectrum.

Healthcare providers gain confidence in diagnoses, patients receive lower radiation doses, and institutions maintain efficiency. Meanwhile, the company locks in competitive positioning by leveraging specialized data and protected algorithms.

Investment Outlook

Izotropic’s integration of a proprietary AI reconstruction algorithm into IzoView represents more than a technical upgrade; it marks a strategic inflection point. Fifteen years of data, a novel approach that fits clinical workflows, and a robust intellectual property strategy together create a moat that general-purpose AI cannot cross.

As imaging converges with artificial intelligence, IzoView is positioned not just to participate but to lead. In a market where most AI promises fade in translation to practice, Izotropic offers a rare case where innovation, data, and protection align to create an unassailable competitive advantage.

For more information, visit the company’s website at www.IzoCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to IZOZF are available in the company’s newsroom at ibn.fm/IZOZF

• Advanced processing technology allows the company to re-process mine waste into scalable gold and silver production.
• Latest PEA update for Quebec’s Montauban project indicates clear path to production.
• The company has entered a binding memorandum to form a joint venture in Colombia for the development and reprocessing of gold and silver-bearing tailings.

ESGold (CSE: ESAU) (OTCQB: ESAUF) recently released its updated PEA (Preliminary Economic Assessment) for the company’s Montauban Gold-Silver Project in Quebec, verifying the projects positive economics and path to production (https://ibn.fm/o6nCU). The updated PEA confirms Montauban’s transformation into a production asset, including: 

• low capex,
• high-margin tailings reprocessing, and the
• infrastructure in place to achieve first production in the near-term

Importantly, ESGold benefits from more than C$20 million in tax-loss carry forwards, which are expected to substantially offset taxable income during the first three years of production, enhancing early-stage free cash flow.

The company is introducing advanced processing technology that re-processes mine waste into scalable gold and silver production, as also revealed in its proposed fully permitted joint venture in Colombia (https://ibn.fm/JqoIH). ESGold is building on its Québec pilot with a scalable, innovative model designed to replicate and grow across the Americas.

In Colombia, the company announced that it has now entered a binding memorandum of understanding with Colombia’s Planta Magdalena S.A.S. (“Planta”) to form the JV with the aim of developing and reprocessing fully permitted, gold- and silver-bearing tailings in that country’s Department of Bolívar.

The Bolívar JV marks ESGold’s first expansion of its scalable tailings to cash flow model beyond Québec, a key test project for commencing similar operations across multiple jurisdictions. The announcement showcases ESGold’s potential for scalable production is at par with leading mining companies that are leveraging strategic planning and advanced technology to strengthen their international position.

By mining responsibly, the company is not only unlocking reserves of mineral wealth but also turning mining waste into sustainable growth, a win-win for ESGold.

For more information, visit the company’s website at https://esgold.com.

NOTE TO INVESTORS: The latest news and updates relating to ESAUF are available in the company’s newsroom at https://ibn.fm/ESAUF

• Company releases report updating status of proprietary 12-lead ECG synthesis software for arrhythmia assessment.
• Earlier this year, HeartBeam submitted its software application to the U.S. Food and Drug Administration.
• Plans will ensure that healthcare providers and patients can seamlessly integrate the HeartBeam system into clinical workflows and home-monitoring routines.

In its most recent quarterly update, HeartBeam (NASDAQ: BEAT) is reporting that the company is on the verge of revolutionizing cardiac diagnostics with its groundbreaking ECG technology. The company is actively preparing for FDA 510(k) clearance of its innovative 12-lead ECG synthesis software for arrhythmia assessment while executing comprehensive commercial readiness plans for a technology that could transform how heart health is monitored both in clinical and home settings (https://ibn.fm/dz7rY).

“In the quarter, we continued to engage in positive and productive discussions with the FDA on the 12-lead ECG synthesis software submission for arrhythmia assessment, and we continue to anticipate clearance by the end of the year. . . . That clearance, together with our foundational clearance, will form the basis for our commercial launch,” said HeartBeam CEO Robert Eno. “We continue to make significant progress with commercial readiness plans, which is positioning us for a successful launch following 510(k) clearance of our 12-lead synthesis software.”

Earlier this year, HeartBeam submitted its 12-lead ECG synthesis software application to the U.S. Food and Drug Administration (“FDA”). The FDA submission was supported by robust clinical evidence and data demonstrating both safety and effectiveness. The company is engaged in ongoing discussions with the FDA regarding its 510(k) application and anticipates clearance by the end of 2025. FDA clearance would mark a major milestone, allowing HeartBeam to expand access to this cutting-edge technology beyond clinical environments.

To prepare for commercial launch, HeartBeam has developed comprehensive readiness plans. These plans include finalizing a cardiology reader service that allows on-demand physician review of synthesized 12-lead ECGs, establishing customer service infrastructure and implementing contract manufacturing and logistics systems. The goal is to ensure that healthcare providers and patients can seamlessly integrate the HeartBeam system into clinical workflows and home-monitoring routines.

HeartBeam’s innovative approach has been recognized within the medical industry. The company has received more than 20 patents for its cardiac diagnostic technology, highlighting the uniqueness of its methods and the potential impact on heart care. In addition, HeartBeam was awarded the Innovation Award in Remote Cardiac Diagnostics as part of the 2025 Medical Device Network Excellence Awards for its groundbreaking ECG technology, and was named a finalist in the 2025 Octane High Tech Awards, which recognizes innovators, entrepreneurs and technology leaders with a presence in Orange County. These industry awards further validate the clinical relevance and technological ingenuity of HeartBeam’s solutions.

Looking forward, HeartBeam plans to initiate commercialization immediately upon receiving FDA clearance. The company’s vision is to empower patients and healthcare providers by offering a portable, cable-free ECG solution that combines clinical-grade accuracy with ease of use. This innovation is poised to reduce the burden on healthcare facilities, improve patient engagement, and increase the availability of high-quality cardiac monitoring, particularly in underserved areas or for patients requiring frequent arrhythmia assessments.

The traditional 12-lead ECG is essential for timely and accurate treatment decisions and is the cornerstone of cardiac care. Despite its clinical value, traditional 12-lead ECG systems are cumbersome, requiring multiple electrodes and wires, and are typically restricted to hospital or clinic use. This limits accessibility for patients and may result in delays in care.

HeartBeam’s synthesis software addresses these limitations by generating a full synthesized 12-lead ECG from a single, compact device for arrhythmia assessment. The system captures signals from three distinct directions and uses advanced algorithms to reconstruct a complete synthesized 12-lead waveform (https://ibn.fm/ldKfq). This approach reduces patient setup time, eliminates the inconvenience of external cables, and facilitates at-home or remote monitoring. The synthesized ECG maintains high fidelity, ensuring that physicians receive the same level of diagnostic detail as traditional systems. Clinical data from the pivotal VALID-ECG study demonstrated a 93.4% overall diagnostic agreement, confirming that HeartBeam’s software can accurately support assessment of arrhythmias.

As the healthcare industry increasingly embraces telemedicine and remote patient monitoring, HeartBeam’s 12-lead ECG synthesis software represents a significant leap forward. By providing a high-fidelity, multidirectional signals of the heart in a compact form factor, the system stands to transform cardiac care, making it more accessible, efficient and patient centered. HeartBeam continues to advance its mission of modernizing heart health monitoring, offering both physicians and patients the tools needed for proactive and informed cardiovascular care.

For more information, visit www.HeartBeam.com.

NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

• Exclusive U.S. patent rights for computer-aided diagnosis (“CADx”) with breast CT secured through a global license with the University of California
• CADx planned as a post-market software upgrade, creating dual revenue streams via upgrade incentives and licensing
• Patent exclusivity paired with proprietary machine-learning reconstruction establishes a durable moat in dedicated breast imaging

The AI Integration Challenge in Medical Imaging

Artificial intelligence has long promised to revolutionize radiology, but most applications remain stuck between theoretical potential and real-world limitations. CADx systems can enhance detection, yet they face hurdles: lack of specialized datasets, workflow disruptions, and intellectual property barriers.

In breast imaging, the stakes are higher. Nearly half of screening patients present with dense breast tissue, where overlapping structures can mask cancers. General-purpose AI retrofits struggle to overcome these limitations. True innovation requires purpose-built platforms that integrate AI from the ground up.

Izotropic (CSE: IZO) (OTCQB: IZOZF) is addressing this head-on, securing exclusive rights to the only U.S. patent for CADx with breast CT, positioning its IzoView system as the first platform built for seamless AI integration in dedicated breast imaging.

Patent Acquisition Creates Strategic Differentiation

IzoView, Izotropic’s flagship 3D breast CT system, offers a powerful imaging alternative bridging the gap between DBT and MRI. The newly licensed CADx patent marks more than a technical addition; it creates clear separation from competitors.

CADx analyzes images to estimate malignancy likelihood, giving radiologists faster, more confident decision support. In breast imaging, CADx addresses the diagnostic gaps left by mammography, DBT, and MRI, whether it’s density masking cancers or overwhelming volumes of data.

The patent covers CADx specifically for breast CT. That technical specificity creates protection against competitors trying to bolt AI onto existing systems. Unlike generalized CADx adaptations, Izotropic’s exclusive license ensures only IzoView can legally integrate this capability into dedicated breast CT.

Phased Rollout Maximizes Market Potential

Izotropic is pursuing a phased commercialization strategy. IzoView will debut without CADx but with its proprietary machine-learning reconstruction algorithm, trained on 15 years of breast CT data, that enhances image quality at low radiation doses.

CADx will arrive as a post-market software upgrade, creating dual opportunities: early adopters gain integration incentives, while Izotropic establishes recurring revenue through software licensing. This approach allows the company to penetrate the market quickly, then layer on AI enhancements as regulatory approvals and workflow demand align.

Competitive Moat Through Integrated AI Architecture

The CADx patent complements Izotropic’s reconstruction algorithm, protected as a trade secret. Together, they form a multi-layered moat that competitors will find difficult to breach.

Most medical AI systems exist as standalone overlays, requiring extra hardware or workflow adjustments. IzoView avoids these pitfalls: both the platform and its AI were designed specifically for breast CT, ensuring seamless integration.

With CADx patent exclusivity blocking rival systems, and its reconstruction algorithm leveraging a dataset competitors cannot replicate, Izotropic has effectively locked down the high ground in breast CT AI.

Market Implications and Revenue Diversification

The patent’s commercial implications extend well beyond technical differentiation. In medical imaging, software upgrades increasingly drive growth, enabling providers to add functionality without costly equipment replacement.

For Izotropic, CADx unlocks recurring software licensing revenue that complements hardware sales. As IzoView’s installed base grows, this creates a compounding model of upfront system sales plus ongoing software monetization.

Exclusive CADx rights ensure IzoView is the only breast CT platform offering this level of AI integration, creating a sustainable competitive advantage as AI adoption accelerates across healthcare.

Investment Positioning

Izotropic’s CADx patent represents a pivotal milestone: it secures protected AI capabilities that extend the company’s existing technical leadership while creating software-driven revenue opportunities.

The commercialization strategy is pragmatic: launch first with IzoView’s core imaging strengths, then expand functionality with AI upgrades that enhance diagnostic accuracy and expand revenue per installation.

For investors, the combination of specialized hardware, protected AI software, and recurring revenue potential defines a compelling story. In an AI landscape where most competitors chase generalized solutions, Izotropic is carving out a defendable, first-mover position in one of the most challenging and valuable imaging domains: breast cancer detection.

For more information, visit the company’s website at www.IzoCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to IZOZF are available in the company’s newsroom at ibn.fm/IZOZF

• Adageis provides AI-powered healthcare software designed to simplify value-based care adoption.
• The company’s patented ProActive Care Platform integrates with leading electronic health record (“EHR”) systems.
• The platform emphasizes simplicity, visibility into insurance contracts, and long-term financial gain for providers.
• Providers can use the system to identify high-value services, track reimbursements, and manage complex contracts.
• Adageis currently covers more than 260,000 patient lives, with ongoing growth expected.

Adageis, a growing healthcare technology company with a patented AI-driven platform, is positioning its software as a practical solution for providers seeking clarity in the transition from fee-for-service to value-based care. By focusing on simplicity, contract visibility, and measurable financial outcomes, the firm aims to address one of the most pressing challenges in U.S. healthcare: how to reward high-quality care with appropriate compensation.

Healthcare providers often struggle with the complexity of insurance contracts and incentive structures. Adageis offers an AI-powered platform that identifies where clinics can maximize revenue while maintaining patient care standards. This functionality is especially important for organizations such as Accountable Care Organizations (“ACOs”), Clinically Integrated Networks (“CINs”), and Independent Physician Associations (“IPAs”).

By giving practices a clearer picture of their contracts, the system allows them to see what they should be earning for the services they provide. For newer practices, Adageis can also highlight which contracts offer the best financial opportunities, easing the shift toward value-based care.

Adageis’ technology also works as an advocate for clinics by revealing whether providers are being compensated fairly under their insurance agreements. High-performing medical groups gain transparency into how much revenue they should expect, based on quality metrics and contract terms. This visibility can make a difference in negotiations with insurers and in planning financial strategies for growth.

The company’s platform enables clinics to monitor their financial progress over time, showing how rewards for high-quality care translate into tangible revenue.

While the platform has its roots in healthcare delivery, Adageis has rebranded its system as a fintech AI platform. The company emphasizes that its tools are not just about patient outcomes but also about revenue optimization. By connecting care delivery with financial performance, the system helps providers measure both quality metrics and their economic value.

This approach aligns with the broader healthcare shift toward value-based care, which prioritizes patient outcomes and cost efficiency over volume-based billing.

Adageis’ ProActive Care Platform brings several core features to users. Its Value-Based Care Engine is designed to manage the entire transition to value-based care. A Patented Risk Engine (“PRE”) identifies high-risk patients and care gaps, supporting early interventions. The platform also enables proactive monitoring of patient health, improving care efficiency beyond office visits.

Integration remains a key selling point. Adageis’ API connects with major EHR systems such as Epic, Cerner, AthenaHealth, eClinicalWorks, and Allscripts. By embedding into existing workflows, the company reduces the barriers to adoption often associated with new healthcare software.

As of August 2025, Adageis’ platform covers over 500,000 patient lives, a figure the company expects will continue to grow as more practices adopt value-based models. The company has also signaled that it is working with investors on additional solutions aimed at supporting small practices, a segment that often lacks the resources to manage complex value-based care transitions.

Adageis’ combination of AI, contract visibility, and financial monitoring places it at the intersection of healthcare technology and financial analytics. The company’s strategy, emphasizing simplicity, visibility, and measurable financial gain, is designed to appeal to both providers seeking operational efficiency and investors looking for scalable healthcare technology platforms. With a patented platform, growing patient coverage, and an emphasis on practical integration, Adageis is positioning itself as a key player in the expanding market for value-based care solutions.

For more information, visit the company’s website at www.Adageis.com.

NOTE TO INVESTORS: The latest news and updates relating to Adageis are available in the company’s newsroom at https://ibn.fm/Adageis

• Nightfood Holdings recently completed its first hotel acquisition in a $31 million deal with Victorville Treasure Holdings, LLC
• This acquisition, and another that’s near closing, serve as the foundation of Nightfood’s hospitality platform and its first Robotics-as-a-service (“RaaS”) innovation site
• The company plans to apply their robotics with everything from housekeeping to food service, to front-of-house

Nightfood Holdings (OTCQB: NGTF), a hospitality technology company looking to redefine hospitality with AI-powered robotics, recently announced the $31 million deal Victorville Treasure Holdings, LLC, the owner of a 155-room Holiday Inn located in Victorville, California. The $31 million includes $5 million in performance-based earnout consideration.

The company already has a deal for a second property in the works, as well. These properties are set to serve as the foundation of Nightfood’s hospitality platform, and ensures the company is on the cutting edge of hotel automation.

The property in Victorville is being transformed into Nightfood’s first Robotics-as-a-service (“RaaS”) innovation site, and will be used for deploying automations, testing them, and benchmarking across multiple brands.

Some early solutions are already installed, such as their laundry helper robot. Robotics deployment will expand in future phases and use robots to help with housekeeping, food service, and front-of-house duties.

When talking about the first property, Nightfood’s CEO Jimmy Chan said “Victorville is our first automation blueprint. It’s where we test, learn, and set the bar for the next generation of smart hotel operations.” He also added that Nightfood is “building more than a portfolio—we’re creating the framework for how hotels can operate with AI”.

About Nightfood Holdings Inc.

Nightfood Holdings is a company that seeks to use strategic acquisitions and AI-powered robots to redefine the hospitality industry. It hopes to set the new standard for cost reduction, efficiency, and optimization in hospitality, by integrating automation directly with hospitality assets.

For more information, visit the company’s website at NightfoodHoldings.com.

NOTE TO INVESTORS: The latest news and updates relating to NGTF are available in the company’s newsroom at https://ibn.fm/NGTF

• SuperCom offers advanced modular EM technology that addresses rising global demand for cost-effective public safety solutions, as governments seek alternatives to incarceration and tools for reducing recidivism.
• SuperCom’s PureSecurity(TM) platform supports multiple applications, from probation monitoring to domestic violence prevention.
• The company has secured more than 30 U.S. contracts in under a year, expanding into 11 states, while international diversification, including national contracts in Israel and Europe, provides important stability alongside U.S. growth.
• Strong financial performance in H1 2025 shows improved profitability, margins, and balance sheet strength.

Electronic monitoring (EM) is emerging as one of the fastest-growing areas in the corrections and public safety market. With governments under pressure to reduce incarceration costs, manage overcrowded prisons, and provide rehabilitative options, EM technologies are being adopted as cost-efficient, scalable alternatives. Research across multiple jurisdictions has shown EM programs can reduce reoffending by approximately 50%, underscoring both their effectiveness and long-term relevance.

SuperCom (NASDAQ: SPCB), a global provider of secured e-Government, IoT, and cybersecurity solutions, is uniquely positioned to capitalize on this trend. The company provides a modular platform, PureSecurity(TM), that integrates GPS, RFID, and cloud-based monitoring capabilities into a suite of products designed for different use cases.

Its components include:

• PureOne(TM), wearable GPS tracking bracelet.
• PureShield(TM), used in domestic violence cases to enforce movement restrictions.
• PureProtect(TM), a mobile app that alerts victims when restrictions are breached.
• PureMonitor(TM), real-time monitoring software for law enforcement agencies.

The platform also includes a range of additional devices and modules, such as PureCom, PureTag, PureBeacon, and PureTrack, that are deployed based on the unique needs of each program or jurisdiction.

This modular approach allows correctional and law enforcement bodies to tailor solutions to their unique needs, making SuperCom’s platform adaptable across geographies and legal frameworks. For investors, this provides visibility into recurring revenue streams, as agencies pay on a per-unit basis with opportunities to scale over time.

SuperCom has significantly expanded its footprint in the U.S. corrections market. Since mid-2024, the company has signed over 30 contracts and entered 11 new states. These agreements are structured on recurring revenue models, ensuring predictable cash flow (https://ibn.fm/nV8Va).

Notable projects include:

• A Tennessee contract transitioning GPS programs to SuperCom’s technology.
• A Virginia project where SuperCom displaced an incumbent provider.
• A statewide procurement agreement with the North Carolina Sheriff’s Association.
• A second Alabama contract in August 2025, awarded through a customer referral.

The Alabama agreement is particularly telling, as it reflects client satisfaction that translates into further adoption. According to company statements, referrals have become a recurring pattern in markets where SuperCom established a presence, reinforcing its ability to win and retain business.

While the U.S. is now the company’s main focus, SuperCom continues to build internationally. Alongside Electra Security, it secured a national EM contract with the Israel Prison Service, supplying more than 1,500 PureSecurity units. In Europe, the company has won over 15 nationwide projects, diversifying its revenue sources and demonstrating the global applicability of its solutions.

Behind its market traction, SuperCom’s financials provide a compelling case for investors. In the first half of 2025, revenue totaled $14.2 million, roughly in line with the prior year (https://ibn.fm/WMyO4). However, profitability improved significantly:

• Gross profit rose 15% to $8.7 million.
• Gross margin expanded to 61.2%.
• Net income jumped 79.5% to $5.3 million.
• Non-GAAP net income reached $7.4 million.
• EBITDA increased 41% to $5.1 million.

Balance sheet metrics also strengthened. Cash and equivalents more than doubled to $15 million compared with $5.7 million a year earlier. Working capital rose to $40.8 million, and the book value of equity doubled to $37.3 million.

Second-quarter results echoed this trend, with gross margins improving and operating income more than doubling to $1.1 million.

The combination of a growing market, proven technology, and improved financial performance strengthens SuperCom’s investment appeal. The recurring-revenue nature of EM contracts provides stability, while rapid U.S. expansion and international diversification offer growth potential.

CEO Ordan Trabelsi has emphasized that the U.S. market is the company’s priority, given its size and attractive economics. The focus on scaling through referrals and displacing legacy systems suggests the company can build competitive momentum without relying solely on pricing. “Over the past 12 months, we sharpened our focus in the United States, where the market opportunity is substantially larger and the economics are more attractive, and we secured over 30 new contracts and entered 11 states in less than a year,” Trabelsi added. “This demonstrates our proven ability to deliver superior technology and expand rapidly in the electronic monitoring market.”

For more information, visit the company’s website at www.SuperCom.com.

NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at https://ibn.fm/SPCB

• AI Maverick Intel is a tech company that provides AI-powered customer acquisition to optimize how businesses engage with leads and prospects
• It has the vision of eliminating friction from the process, and helping businesses replace heavy traditional outreach efforts with modern, streamlined, and automated engagement
• The company is led by CEO Wayne Cockburn, an experienced executive with over two decades of board experience across numerous businesses

AI Maverick Intel (OTC: BINP) is a technology-forward organization that focuses on improving how companies acquire new customers. Traditional methods are time-consuming, resource-heavy, and intensive, and AI Maverick Intel uses AI and technology to optimize the process.

The company has the vision to eliminate friction in the process and empower organizations to connect more efficiently with their targets. It helps reveal insights about your customer journey and show how key members of your audience interact with the company, while also using AI and machine learning to help refine and personalize your communication efforts in real time.

AI Maverick Intel helps you stay ahead in fast-moving industries and uses proprietary technology to power its AI-driven prospecting engine. This technology helps build dynamic customer profiles, which highlight buying intent, position changes, and customer preferences.

It also fine-tunes your messages to ensure they resonate well with your audience, and automates sales tasks like follow-ups, discovery questions, and objections, which traditionally needed to be done manually.

This platform can help companies in a variety of industries like healthcare, insurance, biotech, and transportation scale and automate customer outreach and acquisition, which saves both time and resources.

AI Maverick Intel is headquartered in Dallas, Texas, and is led by experienced business executive Wayne Cockburn. He has 25 years of board experience on both private and public companies, in industries like financial services and healthcare. He’s held several positions throughout his long career, including Executive Vice President of MedX Health Corp, Chairman of Niiomed Inc., and President of Pathway Health Corp.

About AI Maverick Intel

AI Maverick Intel Inc. is a tech company that helps businesses modernize and streamline the customer acquisition process. It uses AI to automate communication efforts and provide useful data-driven insights to make better and more informed decisions.

For more information, visit www.AIMaverickIntel.com.

NOTE TO INVESTORS: The latest news and updates relating to BINP are available in the company’s newsroom at ibn.fm/BINP

• Datavault AI holds more than 70 issued and pending patents across AI, blockchain, tokenization, and acoustic science, including nine new patent allowances secured in 2025.
• The company is actively commercializing its stablecoin and tokenization technologies through new digital asset exchanges focused on carbon credits and political advertising.
• Its partnership network — including IBM WatsonX, NYIAX, Burke Products, Turner Global Media, and LifeGenix Institute — supports market access across defense, healthcare, digital media, and data licensing.
• The company’s patented audio platforms, including ADIO(R) and SyncIN(TM), enable secure ultrasonic transactions and mobile triggers across broadcast, retail, and streaming environments.
• With a vertically integrated technology stack and high-margin licensing model, Datavault AI is positioned to scale within the emerging Web 3.0 data economy.

Datavault AI (NASDAQ: DVLT) is a Web 3.0 infrastructure company advancing AI-driven data monetization, valuation, and tokenization technologies across both public and private sector applications. Through a combination of proprietary platforms, high-performance computing, and patent-protected solutions, the company enables enterprises, institutions, and governments to extract meaningful value from their data while ensuring regulatory compliance, identity security, and scalability.

With a growing portfolio of strategic partnerships and acquisitions, Datavault AI is building a platform-based business model that unifies the worlds of blockchain, AI, and immersive digital experiences.

The company is headquartered in Beaverton, Oregon.

Products

Datavault AI delivers proprietary technologies across two core operating divisions: Acoustic Science and Data Science. Together, these divisions enable Datavault AI to create, deliver, and license programmable data experiences — from inaudible tone-based ads and stablecoin transactions to digital identity records and tokenized real-world assets.

Acoustic Science Division

The Acoustic Science Division encompasses Datavault AI’s suite of patented audio-based technologies designed for secure communication, immersive engagement, and ultrasonic data delivery. Core offerings include ADIO(R), a data-over-sound platform that enables inaudible tone-triggered transactions and real-time consumer engagement across broadcast, retail, and streaming environments. The SyncIN(TM) system, acquired from Turner Global Media, expands this reach by embedding imperceptible tones into live media to trigger mobile responses and facilitate stablecoin transactions at scale.

Also under this division is Sumerian(R), which leverages microtransponders, polymers, and molecular markers to create crypto anchors for authenticating real-world assets. This solution enables real-time object verification and supports the creation of trusted digital twins. Finally, WiSA(R) audio technologies deliver wireless, multichannel HD sound transmission with proprietary IP covering spatial control, synchronization, and interference cancellation. These systems are used across consumer electronics, event venues, and enterprise installations.

Data Science Division

The Data Science Division centers on Datavault AI’s AI-integrated tools for data transformation, valuation, and compliance. Flagship products include DataVault Bank(R), which tokenizes enterprise data into structured, tradable assets; DataScore(R), a compliance-driven scoring system for assessing data quality; and DataValue(R), an AI-powered pricing engine that assigns real-time monetary value to digital assets. These solutions are built in collaboration with IBM WatsonX and serve as the foundational infrastructure for Datavault AI’s tokenization and licensing platforms.

Additional applications include VerifyU(TM), a credentialing solution designed to support NIL compliance and lifelong academic and professional identity verification. Commercial implementations span verticals including education, government, sports, and preventative health, often in partnership with organizations such as LifeGenix Institute and NYIAX.

Market Opportunity

Datavault AI is strategically aligned with emerging trends across Web 3.0 infrastructure, digital identity, and AI-based data monetization. The Web 3.0 blockchain market is projected to grow from $4.84 billion in 2024 to $135.34 billion by 2032, according to Straits Research, creating long-term demand for scalable, secure data platforms.

Core to this opportunity is Datavault AI’s valuation and tokenization stack — including DataValue(R) and DataScore(R) — which serve data compliance and monetization use cases within sectors forecast to exceed $700 billion by 2025, per Transparency Market Research.

The company is also pursuing early-stage opportunities through its carbon credit tokenization IP, and its infrastructure partnerships in credentialing, NIL licensing, and Web 3.0-triggered advertising. SyncIN and ADIO(R) are positioned to support engagement use cases in privacy-first media and retail environments.

Looking forward, Datavault AI aims to support the development of tokenized commodity exchanges — including pre-mining assets such as geothermal energy and rare earth elements — pending regulatory alignment and platform integration.

Leadership Team

Nathaniel T. Bradley, Chief Executive Officer and Director, is a co-founder of Datavault AI and the architect of its patented technology portfolio. He holds more than 70 U.S. and international patents and previously served as CTO of Marathon Patent Group and founder of AudioEye.

Sonia Choi, Chief Marketing Officer, leads the company’s branding, licensing, and enterprise development initiatives. A patented inventor in marketing and inclusion technologies, she is also a serial entrepreneur with a track record of building businesses and delivering high-impact campaigns and strategies for Fortune 500 companies.

Jeff Jones, Chief Technology Officer, has led global SaaS platform development for two decades, delivering digital accessibility, telecommunications, and compliance solutions licensed by multiple Fortune 500 companies.

Brett Moyer, Chief Financial Officer and Director, is the former CEO of WiSA Technologies and a veteran executive with past leadership roles at Zenith Electronics, Focus Enhancements, and multiple educational institutions.

For more information, visit the company’s website at https://datavaultsite.com.

NOTE TO INVESTORS: The latest news and updates relating to DVLT are available in the company’s newsroom at https://ibn.fm/DVLT

• The system’s design emphasizes user friendliness and portability while aligning with the growing trend toward remote patient monitoring and telemedicine.
• HeartBeam to initiate commercial launch upon FDA clearance of 12-lead ECG synthesis software, anticipated later this year.

For decades, the traditional 12-lead electrocardiogram (“ECG”) has been the gold standard in cardiac diagnostics, including arrhythmia assessment, offering a comprehensive assessment of the heart’s electrical activity. However, traditional 12-lead ECG systems often come with limitations such as cumbersome setups and restricted accessibility. HeartBeam (NASDAQ: BEAT) is addressing these challenges by developing the HeartBeam System, the first cable-free, high-fidelity ECG system that captures the heart’s electrical signals from three distinct directions and synthesizes the signals into a 12-lead ECG, enabling comprehensive arrhythmia assessment outside clinical settings. This innovative approach aims to revolutionize cardiac care by providing patients with the ability to monitor their heart health conveniently and accurately.

Despite their effectiveness, traditional 12-lead ECG systems have several limitations. The setup process requires an in-clinic trained clinician, can be time-consuming and uncomfortable for patients, requiring multiple electrodes and wires. Additionally, these systems are typically confined to clinical environments, limiting their accessibility for patients when symptoms occur which may result in delays in seeking care.

HeartBeam is addressing these challenges with its innovative HeartBeam System (https://ibn.fm/facCM). Unlike traditional ECG devices, the HeartBeam System is cable free and compact, designed for at-home use. The system captures high-fidelity ECG signals from three distinct directions, providing a comprehensive view of the heart’s electrical activity, and synthesizes the signals into a familiar 12-lead ECG view. This approach enhances the accuracy of arrhythmia detection and allows for real-time monitoring of heart health.

In December 2024, HeartBeam announced that the U.S. Food and Drug Administration (“FDA”) granted 510(k) clearance for the foundational model of the HeartBeam System for comprehensive arrhythmia assessment (https://ibn.fm/hqTmA). This clearance signifies that the system meets the FDA’s rigorous standards for safety and effectiveness, paving the way for its broader adoption in clinical and home settings. The 12-lead ECG synthesis software, which converts the signals captured from three distinct directions and synthesizes the signals into a 12-lead ECG output, is currently under FDA review with clearance anticipated later this year. The HeartBeam System’s ability to provide detailed synthesized 12-lead ECG readings outside of a clinical environment for arrhythmia assessment represents a significant advancement in patient-centered cardiac care.

The HeartBeam System’s design emphasizes user friendliness and portability. The device is the size of a credit card, making it easy for patients to use at home or on the go. Patients can capture their ECG by placing the device on their chest for 30 seconds, after which the data is transmitted securely to an on-call cardiologist for review. This streamlined process enables timely interventions when necessary.

Beyond its technical capabilities, the HeartBeam System aligns with the growing trend toward remote patient monitoring and telemedicine. By enabling patients to monitor their heart health from home, the system reduces the burden on healthcare facilities and allows for more personalized care. This approach is particularly beneficial for individuals with chronic conditions or those living in underserved areas where access to specialized care may be limited.

HeartBeam’s commitment to innovation is further demonstrated by its ongoing research and development efforts. The company continues to refine its technology to enhance the accuracy and usability of the HeartBeam System. Future iterations may incorporate advanced features such as artificial intelligence algorithms to assist in interpreting ECG data and providing actionable insights for patients and healthcare providers.

While traditional 12-lead ECG systems have been instrumental in cardiac diagnostics, their limitations in terms of accessibility and convenience have highlighted the need for more advanced solutions. HeartBeam’s development of the HeartBeam System represents a significant step forward in addressing these challenges. By providing a cable-free, high-fidelity ECG system that captures comprehensive heart signals from multiple directions, HeartBeam is poised to transform the landscape of cardiac care, making it more accessible, efficient, and patient-centered.

For more information, visit www.HeartBeam.com.

NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT